Results 221 to 230 of about 70,747 (277)

Interferon beta-1b and childhood multiple sclerosis

Pediatric Neurology, 1999
The long-term treatment with interferon beta-1b of a 7-year-old male with relapsing-remitting multiple sclerosis is documented. Thirty-two months after initiating treatment, he demonstrates dramatic clinical improvement, without relapse, despite high titers of neutralizing antibodies to interferon beta-1b.
Adams, Alexa B., Tyor, William R., Holden, Kenton R.   +2 more
openaire   +3 more sources

Interferon beta-1b treatment does not induce autoantibodies

Neurology, 2005
There is little information regarding the potential of interferon beta (IFNbeta) to induce or exacerbate autoimmune disease. Existing data from uncontrolled studies are contradictory and do not differentiate between autoimmune dysfunction, which is frequent in patients with multiple sclerosis (MS), and untoward drug effects.To evaluate the impact of ...
C. H. Polman, L. Kappos, F. Dahlke, R. Graf, K. Beckmann, T. Bogumil, POZZILLI, Carlo, A. J. Thompson, European Study Group On Interferon Beta B. In Spms   +8 more
openaire   +4 more sources

Interferon beta-1b injection site reactions and necroses

Multiple Sclerosis Journal, 1998
We conducted a comprehensive review of selected adverse event reports that were submitted to the Food and Drug Administration (FDA) for interferon beta-1b during the first 30 months following licensure. The adverse events reviewed were injection site reactions, injection site necroses, and non-injection site necroses.
A R, Gaines, F, Varricchio
openaire   +2 more sources

▼Interferon beta-1b - hope or hype?

Drug and Therapeutics Bulletin, 1996
In November 1995, the European Commission gave approval for interferon beta-1b (Betaferon - Schering) to be marketed throughout the European Union "for the reduction of frequency and degree of severity of clinical relapses in ambulatory patients with relapsing/remitting multiple sclerosis".
openaire   +2 more sources

Pharmakologie von Interferon beta-1b

2013
Multiple Sklerose (MS) ist gekennzeichnet durch eine chronische Entzundung, die assoziiert ist mit einer Autoimmunreaktion an neuralem Gewebe. Durch dieses Geschehen kommt es zur Zerstorung der Myelinscheiden, wodurch demyelinisierende Lasionen in der weisen Substanz von Gehirn und Ruckenmark entstehen, die die Nervenleitung massiv storen und mit ...
Theodor Dingermann, Ilse Zündorf
openaire   +1 more source

Interferon-beta-1b

Reactions Weekly, 2022
openaire   +2 more sources

Severe Vaginal Bleeding Associated with Recombinant Interferon Beta-1B

Annals of Pharmacotherapy, 1997
OBJECTIVE: To report a case of severe vaginal bleeding associated with interferon beta-1b (IFN-β). CASE SUMMARY: A 19-year-old white woman diagnosed with multiple sclerosis was treated with IFN-β 4 million IU every other day for 1 month. After 1 month, the dosage was increased to 8 million IU.
L A, Pakulski, L M, DiMarco
openaire   +2 more sources

Interferon-beta-1b

Reactions Weekly, 2023
openaire   +1 more source